DDInter1867 DDInter1581
A phenothiazine used as an antipsychotic agent and as an antiemetic.
Repaglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Repaglinide induces an early insulin response to meals decreasing postprandial blood glucose levels. It should only be taken with meals and meal-time doses should be skipped with any skipped meal. Approximately one month of therapy is required before a decrease in fasting blood glucose is seen. Meglitnides may have a neutral effect on weight or cause a slight increase in weight. The average weight gain caused by meglitinides appears to be lower than that caused by sulfonylureas and insulin and appears to occur only in those naïve to oral antidiabetic agents. Due to their mechanism of action, meglitinides may cause hypoglycemia although the risk is thought to be lower than that of sulfonylureas since their action is dependent on the presence of glucose. In addition to reducing postprandial and fasting blood glucose, meglitnides have been shown to decrease glycosylated hemoglobin (HbA1c) levels, which are reflective of the last 8-10 weeks of glucose control. Meglitinides appear to be more effective at lowering postprandial blood glucose than metformin, sulfonylureas and thiazolidinediones. Repaglinide is extensively metabolized in the liver and excreted in bile. Repaglinide metabolites do not possess appreciable hypoglycemic activity. Approximately 90% of a single orally administered dose is eliminated in feces and 8% in urine.
Triflupromazine {u} (Compound) resembles {v} (Compound) Chlorpromazine
Chlorpromazine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Repaglinide
Triflupromazine {u} (Compound) resembles {v} (Compound) Methotrimeprazine
Methotrimeprazine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Repaglinide
Triflupromazine {u} (Compound) resembles {v} (Compound) Chlorpromazine
Chlorpromazine {u} (Compound) binds {v} (Gene) ALB
ALB {u} (Gene) is bound by {v} (Compound) Repaglinide
Triflupromazine {u} (Compound) resembles {v} (Compound) Propiomazine
Propiomazine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Phentermine
Phentermine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Repaglinide
Triflupromazine {u} (Compound) resembles {v} (Compound) Methotrimeprazine
Methotrimeprazine {u} (Compound) causes {v} (Side Effect) Jaundice
Jaundice {u} (Side Effect) is caused by {v} (Compound) Repaglinide
Triflupromazine {u} (Compound) resembles {v} (Compound) Pipotiazine
Pipotiazine {u} (Compound) resembles {v} (Compound) Methotrimeprazine
Methotrimeprazine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Repaglinide
Triflupromazine {u} (Compound) resembles {v} (Compound) Propiomazine
Propiomazine {u} (Compound) resembles {v} (Compound) Chlorpromazine
Chlorpromazine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Repaglinide
Triflupromazine {u} (Compound) resembles {v} (Compound) Thioridazine
Thioridazine {u} (Compound) upregulates {v} (Gene) PPARG
PPARG {u} (Gene) is bound by {v} (Compound) Repaglinide
Triflupromazine {u} (Compound) resembles {v} (Compound) Methdilazine
Methdilazine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Nifedipine
Nifedipine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Repaglinide
Triflupromazine {u} (Compound) resembles {v} (Compound) Desipramine
Desipramine {u} (Compound) resembles {v} (Compound) Promazine
Promazine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Repaglinide
Triflupromazine (Compound) resembles Chlorpromazine (Compound) and Chlorpromazine may cause a moderate interaction that could exacerbate diseases when taken with Repaglinide
Triflupromazine (Compound) resembles Methotrimeprazine (Compound) and Methotrimeprazine may cause a moderate interaction that could exacerbate diseases when taken with Repaglinide
Triflupromazine (Compound) resembles Chlorpromazine (Compound) and Chlorpromazine (Compound) binds ALB (Gene) and ALB (Gene) is bound by Repaglinide (Compound)
Triflupromazine (Compound) resembles Propiomazine (Compound) and Propiomazine may cause a moderate interaction that could exacerbate diseases when taken with Phentermine and Phentermine may cause a moderate interaction that could exacerbate diseases when taken with Repaglinide
Triflupromazine (Compound) resembles Methotrimeprazine (Compound) and Methotrimeprazine (Compound) causes Jaundice (Side Effect) and Jaundice (Side Effect) is caused by Repaglinide (Compound)
Triflupromazine (Compound) resembles Pipotiazine (Compound) and Pipotiazine (Compound) resembles Methotrimeprazine (Compound) and Methotrimeprazine may cause a moderate interaction that could exacerbate diseases when taken with Repaglinide
Triflupromazine (Compound) resembles Propiomazine (Compound) and Propiomazine (Compound) resembles Chlorpromazine (Compound) and Chlorpromazine may cause a moderate interaction that could exacerbate diseases when taken with Repaglinide
Triflupromazine (Compound) resembles Thioridazine (Compound) and Thioridazine (Compound) upregulates PPARG (Gene) and PPARG (Gene) is bound by Repaglinide (Compound)
Triflupromazine (Compound) resembles Methdilazine (Compound) and Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Nifedipine and Nifedipine may cause a moderate interaction that could exacerbate diseases when taken with Repaglinide
Triflupromazine (Compound) resembles Desipramine (Compound) and Desipramine (Compound) resembles Promazine (Compound) and Promazine may cause a moderate interaction that could exacerbate diseases when taken with Repaglinide